Neuralstem Inc (Nasdaq: CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule technologies, has named David J Mazzo, PhD as its director effective 12 June 2019, it was reported yesterday.
Dr Mazzo will replace Stanley Westreich, who is retiring on the effective date.
Dr Mazzo has more than 30 years of experience in the pharmaceutical industry, and currently serves as chief executive officer of Caladrius Biosciences. He has also served as: chief executive officer and as a member of the board of directors of Regado Biosciences Inc, a NASDAQ-listed biopharmaceutical company; president, chief executive officer and a director of Eterna Zentaris Inc and president, chief executive officer and a director of Chugai Pharma USA LLC, a biopharmaceutical company which was the US subsidiary of Chugai Pharmaceutical Co Ltd of Japan. In addition, Dr Mazzo has also held senior management and executive positions in a number of public and private pharmaceutical and biotech companies.
Convergent Therapeutics names new chairman of board of directors
Ionis Pharmaceuticals names new executive vice president, chief global product strategy officer
Cardinal Health names new independent director
Micron Biomedical names new scientific advisor to CEO
MedPharm names new executive chairman
Armonica Technologies names new director
Jazz Pharmaceuticals names new executive vice president and chief financial officer
Jazz Pharmaceuticals names new executive vice president and chief financial officer
Ardigen names new chief commercial officer
AbbVie names new chief executive officer
AMO Pharma collaborates with Population Health Research Institute for tideglusib clinical trial